aNUma develops multi-user virtual reality experiences that utilize principles from psychedelic science and group therapy to enhance mental health and wellbeing. Their platform fosters profound interpersonal connections, resulting in measurable improvements in participants' emotional states, such as increased calmness and happiness.

Apex Labs is developing psilocybin-based pharmaceuticals aimed at treating depression and PTSD, addressing the limitations of current antidepressant therapies which have a 40-60% effectiveness rate and often cause unwanted side effects. The company focuses on creating clinically evaluated drugs that can be prescribed by physicians globally, aiming to establish a new standard of care in mental health treatment.

Awakn Life Sciences is developing medication-assisted treatments (MATs) that target brain circuits associated with addiction, specifically focusing on Alcohol Use Disorder (AUD), which affects millions globally. Their evidence-based approach aims to improve treatment outcomes and reduce relapse rates by enabling patients to engage in psychotherapeutic processes that foster lasting behavioral change.

Beckley Psytech is developing a novel synthetic intranasal formulation of 5-MeO-DMT benzoate, designed to provide rapid and lasting treatment effects for mental health conditions such as Treatment Resistant Depression and Alcohol Use Disorder. The company addresses the significant unmet need for effective and accessible mental health treatments by leveraging next-generation psychedelic compounds that can be administered in a short clinic visit.

Beckley Retreats organizes science-backed psychedelic retreats utilizing psilocybin and ketamine in legal settings for personal growth and well-being. The program follows a structured preparation, immersion, and integration model supported by expert facilitation. They aim to provide transformative experiences that foster clarity, community, and lasting positive change.

Clairvoyant Therapeutics is a biotechnology company focused on developing psychedelic therapies through a rapid clinical trial approach. The company aims to provide effective treatment options for mental health disorders by accelerating the availability of these therapies to patients in need.

Fluence provides continuing education and certification programs for mental health practitioners in psychedelic-assisted therapy and integration, utilizing evidence-based training methods developed by experienced clinicians and researchers. The organization addresses the lack of specialized training in the emerging field of psychedelic therapy, equipping professionals with the necessary skills to effectively support clients in their therapeutic journeys.

Freedom Biosciences is a biotechnology platform developing next-generation neuropsychiatric therapeutics based on ketamine pharmacology. The company focuses on creating novel antidepressants with improved efficacy and safety profiles for debilitating mental health disorders. Their pipeline includes clinical and preclinical programs targeting treatment-resistant depression and comorbid substance use disorders.

The startup develops psychedelics-based neuromodulators by repurposing psychoactive natural products to create therapies for cognitive, mood, and substance use disorders. This approach provides clinicians with targeted treatment options to enhance mental health outcomes.

Psygen manufactures pharmaceutical-grade psychedelic and neuroplastogen active pharmaceutical ingredients (APIs) in a purpose-built facility, utilizing over 50 years of experience in psychedelic chemistry. The company addresses the need for reliable access to these substances for clinical research and therapeutic applications, supporting projects that require LSD, MDMA, and psilocybin.

Quantified Citizen is a mobile health research platform that enables users to track health metrics and participate in research studies using scientifically-validated scales. By providing 100% anonymous data, the platform contributes to global health research while offering personalized insights to improve individual health outcomes.

ReGen develops microbial fertilizers that enhance nutrient delivery to crops by introducing diverse beneficial microbes, promoting early germination and improved yield. This approach reduces reliance on synthetic agrochemicals, regenerates soil health, and increases farmers' productivity and resilience against environmental challenges.

Reset Pharma is developing psilocybin-inspired therapies that aim to reset neural networks in patients facing demoralization due to life-threatening diseases like cancer. By leveraging neuro-biotechnology, the company seeks to enhance the quality of life for terminal patients through targeted mental health interventions.

Sana utilizes machine learning algorithms to create a personalized learning platform tailored for the education sector, enhancing the effectiveness of educational content delivery. The platform addresses the challenge of diverse learning needs by adapting resources to individual student profiles, improving engagement and retention rates.

Sensorium is a clinical-stage biotechnology company focused on developing CNS treatments derived from natural compounds. The company utilizes its proprietary SensAI platform, which integrates chemistry, neuroscience, and pharmacology across over 50 million data relationships to systematically identify therapeutic patterns. This approach has yielded several differentiated drug candidates, including SENS-01, a precision therapy currently in clinical trials for anxiety disorders.

TRIPP is a digital wellness platform that utilizes virtual and augmented reality to provide guided mindfulness and breathwork sessions aimed at improving mental health. By offering immersive experiences, TRIPP helps users manage stress and enhance emotional well-being through accessible, on-demand support.